Example: Heart Attack

Search clinical trials for: Palivizumab

Total 28 results

NCT01006629

Completed

Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children

Conditions: Respiratory Syncytial Virus Infection; Premature Birth; Bronchopulmonary Dysplasia; Congenital Heart Disease
NCT02968173

Completed

A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus

Conditions: Respiratory Syncytial Virus (RSV)
NCT01107535

Completed

Effectiveness of Synagis (Palivizumab) Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus (RSV) Infection

Conditions: Respiratory Syncytial Virus Infection
NCT01466062

Completed

Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions

Conditions: Respiratory Syncytial Virus Infection
NCT02442427

Completed

"Palivizumab Therapy for RSV-bronchiolitis"

Conditions: Respiratory Syncytial Virus-bronchiolitis
NCT00233064

Completed

Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis)

Conditions: Chronic Lung Disease
NCT04540627

Active, not recruiting

Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV

Conditions: Healthy Adult Participants
NCT00316264

Completed

Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season

Conditions: Respiratory Syncytial Virus Infections; Chronic Lung Disease and <= 24 Months of Age or; Premature With Gestational Age <=35 Weeks and <=6 Months of Age
NCT00129766

Completed

Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

Conditions: Respiratory Syncytial Virus Infections
NCT00113490

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children

Conditions: Motavizumab Administration for a Second Season for RSV Prophylaxis
NCT00240929

Completed

A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis)

Conditions: -Unhealthy Children With a History of Prematurity
NCT00538785

Completed

A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease

Conditions: Congenital Heart Disease
NCT03959488

Recruiting

A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

Conditions: Respiratory Syncytial Virus Infections
NCT01297504

Completed

A One-Year Observation of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin America

Conditions: Respiratory Syncytial Virus Infection
NCT01077271

Completed

Compliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - 35 wGA

Conditions: Premature Infants
NCT01155193

Completed

Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany

Conditions: Respiratory Syncytial Virus Infections
NCT01075178

Completed

Retrospective Palivizumab Study in Children With Hemodynamically Significant Congenital Heart Disease

Conditions: Severe Respiratory Syncytial Virus Infection
NCT00014391

Completed

Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation

Conditions: Cancer
NCT01072552

Completed

Effect of Palivizumab on Later Recurrent Wheezing in Preterm Infants

Conditions: Recurrent Wheezing; Wheezing; Asthma
NCT02282982

Completed

Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis

Conditions: Respiratory Syncytial Virus (RSV)
NCT01269528

Completed

Prospective Evaluation of the Efficacy of Palivizumab Administration in Children Born at 29-32 Weeks of Gestation

Conditions: Bronchial Hyperreactivity; Infant, Premature
NCT02016690

Completed

Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immunocompromised Children With Synagis®

Conditions: Respiratory Syncytial Virus Infection
NCT00484393

Completed

Tetracaine Compared to Placebo for Reducing Pain With Palivizumab - A Pilot Study

Conditions: Pain
NCT01537198

Completed

Surveillance of Synagis in Korean Pediatric Patients

Conditions: Respiratory Syncytial Virus Infection
NCT01545245

Completed

Effects of Preventive Treatment for Respiratory Syncytial (RS) Virus Infection During Infancy on Later Atopic Asthma in Preterm Infants

Conditions: Atopic Asthma; Recurrent Wheezing